Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C

[Business Wire] – Gilead Sciences, Inc. today announced data from three Phase 2 open-label studies evaluating the safety and efficacy of an investigational all-oral pan-genotypic regimen containing the nucleotide analog polymerase inhibitor sofosbuvir . . . → Read More: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead Announces Phase 2 Data for Investigational All-Oral Regimen of Sofosbuvir Plus GS-5816 for the Treatment of Chronic Hepatitis C Similar Articles: Stock Update (NYSE:BMY): UPDATE 1-Bristol-Myers pulls U.S. marketing application for hepatitis C treatment Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor Stock Update (NYSE:ABBV): AbbVie files New Drug Submission to Health Canada for its investigational, all-oral, interferon-free therapy for the treatment of hepatitis C